A woman’s use of decongestant medications in the first trimester of pregnancy may raise her child’s risk of certain rare birth defects, according to a small study.
Some types of over-the-counter decongestants, including the popular phenylephrine and pseudoephedrine, were individually linked to rare, specific birth defects of the digestive tract, ear and heart.
“Major birth defects of any kind affect about two to three percent of liveborn infants, so they are rare,” study author Dr. Allen Mitchell said. “The associations we identified involved defects that generally affect less than 1 per 1,000 infants. Some of them may require surgery, but not all are life-threatening.”
Decongestants are some of the most commonly used drugs, however, so fully understanding the consequences of taking them during pregnancy is important, said Mitchell, director of the Slone Epidemiology Center at Boston University.
His team worked with a large collection of data on babies born with birth defects between 1993 and 2010. Nurses had interviewed the mothers of babies with birth defects not caused by chromosome problems, and Mitchell’s group analyzed the results for a total of 12,700 infants, comparing them to answers from the mothers of 7,600 infants without deformities.
Mothers were asked about medications they took while pregnant and in the two months before becoming pregnant.
First-trimester use of phenylephrine, which is found in Sudafed among other products, was tied to an eight-fold higher risk of a heart defect called endocardial cushion defect. And phenylpropanolamine (Acutrim) was also linked to an eight-fold risk of defects of the ear and stomach. All were associations that had been suggested by earlier studies.
But for the first time, the authors found links between first-trimester use of pseudoephedrine (also in Sudafed) and a 3-fold higher risk of so-called limb reduction defects. Use of imidazolines (found in nasal decongestant sprays and eye drops) was tied to an approximate doubling of risk for an abnormal connection between the trachea and esophagus.
“The risks we identified should be kept in perspective,” Mitchell cautioned. “The risk of an endocardial cushion defect among babies whose mothers did not take decongestants is about 3 per 10,000 live births.”
Even the eight-fold increase in risk indicated by the study results, while it sounds large, would translate to a 2.7 in 1,000 chance the baby would have the defect, he said. Assuming the findings are correct, he added, the researchers could not speculate about why these drugs might be linked to this handful of defects.